RNA binding motif protein 27Genealiases: ARRS1 · Psc1
Q-omics provides the consensus-scored RBM27 profile across patient tissues and cancer cell-line models. RBM27 expression is associated with patient survival in 28 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, RBM27 is differentially expressed in 13, with the highest sampling consensus in HNSC. Additionally, RBM27 RNA expression shows 20,649 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight KIRC, HNSC, and ACC as cancer lineages where RBM27 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RBM27 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RBM27 survival associations across molecular data types. RBM27 RNA expression shows survival associations in the most cancer types (28), followed by mutation status (6) and mass-spec protein abundance (7). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RBM27 RNA expression–survival associations across cancer types. High RBM27 expression shows unfavorable associations in ACC, LIHC, KIRP, UVM and HNSC, but favorable associations in KIRC. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for RBM27 RNA expression.
This table summarizes RBM27 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 5. The strongest signals are observed in HNSC for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for RBM27. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RBM27 shows lower tumor expression in THCA and higher tumor expression in HNSC, LIHC, KIRC, KIRP and STAD. The HNSC box plot shows higher RBM27 RNA expression in tumor versus normal tissue (log2 FC = +0.449, t-test p < 0.001).
This table shows molecular features associated with RBM27 in patient tissues and cancer cell lines. In patient samples, RBM27 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, RBM27 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OESOPHAGUS, while CRISPR and shRNA rows add functional-dependency signals in CNS and BLOOD_Lymphoma.
